Maps (MAPS) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
28 Sep, 2026Executive summary
Consolidated revenue for H1 2026 was €13.2M, down 11% year-over-year, mainly due to the absence of non-recurring revenues in the Layers BU from large construction consortia.
Value of production rose 3% year-over-year to €17.9 million, with total revenues up 1% to €16.0 million, driven by growth in Healthcare (+6%) and Energy (+22%) market areas.
Net profit attributable to the group was €374K, compared to €571K in H1 2025, with the decline due to higher depreciation and financial costs.
Recurring fees increased 33% year-over-year, now representing 48% of core revenues, reflecting a shift toward a product-based business model and improved revenue quality.
The group completed the acquisition of 51% of Energy Audit S.r.l., strengthening its Energy BU.
Financial highlights
EBITDA for H1 2026 was €1.08M, down from €1.22M in H1 2025, while another report notes EBITDA grew 3% to €3.1 million, with an EBITDA margin of 19.2%.
Net financial debt increased to €13.5M, mainly due to the Energy Audit acquisition.
Shareholders' equity: €25.7 million (31 Dec 2025: €26.3 million), impacted by share buybacks and M&A.
Total assets rose to €65.9M from €61.9M at year-end 2025.
Net profit margin for H1 2026 was approximately 2.3%–2.8%.
Outlook and guidance
The group expects continued growth in Healthcare and Energy, supported by digitalization trends, recurring revenues, and increased demand for data-driven solutions.
The acquisition of BI Health S.r.l. is expected to strengthen the Healthcare BU's data analytics offering, with completion by November 2026.
Management remains cautious due to macroeconomic and geopolitical uncertainties but is focused on innovation and recurring revenue streams.
Latest events from Maps
- Product-driven growth led by healthcare boosts 2025 revenues, with strong analyst outlook.MAPS
Investor presentation - Product-driven growth in healthcare offset project declines; EBITDA and profit margins narrowed.MAPS
H2 2025 - Healthcare-led product growth and Ellysse acquisition drive strategy as net profit dips.MAPS
H1 2025 - Digital transformation in healthcare and energy drives robust growth and strong future outlook.MAPS
Investor Presentation - 2024 saw record profitability, strong product-driven growth, and a robust outlook to 2027.MAPS
Investor Presentation - Record profitability and product-driven growth position the group for further expansion.MAPS
Investor Presentation - Profitability surged over 50% in H1 2024, with revenues up to €14.7M and improved cash flow.MAPS
H1 2024 - Record profitability and cash flow growth driven by scalable products and healthcare strength.MAPS
H2 2024